A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer.
Jianliang ShenHan-Cheon KimJoy WolframChao-Feng MuWei ZhangHaoran LiuYan XieJunhua MaiHang ZhangZhi LiMaria GuevaraZong-Wan MaoHaifa ShenPublished in: Nano letters (2017)
Ruthenium coordination complexes have the potential to serve as novel theranostic agents for cancer. However, a major limitation in their clinical implementation is effective tumor accumulation. In this study, we have developed a liposome-based theranostic nanodelivery system for [Ru(phen)2dppz](ClO4)2 (Lipo-Ru). This ruthenium polypyridine complex emits a strong fluorescent signal when incorporated in the hydrophobic lipid bilayer of the delivery vehicle or in the DNA helix, enabling visualization of the therapeutic agent in tumor tissues. Incubation of MDA-MB-231 breast cancer cells with Lipo-Ru induced double-strand DNA breaks and triggers apoptosis. In a mouse model of triple-negative breast cancer, treatment with Lipo-Ru dramatically reduced tumor growth. Biodistribution studies of Lipo-Ru revealed that more than 20% of the injected dose accumulated in the tumor. These results suggest that Lipo-Ru could serve as a promising theranostic platform for cancer.
Keyphrases
- energy transfer
- photodynamic therapy
- breast cancer cells
- fluorescence imaging
- papillary thyroid
- mouse model
- circulating tumor
- primary care
- gene expression
- healthcare
- squamous cell
- high throughput
- single molecule
- cell free
- cell cycle arrest
- squamous cell carcinoma
- iron oxide
- single cell
- risk assessment
- fatty acid
- climate change
- young adults
- ionic liquid
- lymph node metastasis
- diabetic rats
- label free